Venture&Growth Archives - Gilde Healthcare

latest news
Venture&Growth

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led by Gilde Healthcare Partners and Lightstone Ventures, including participation from existing investors. ProVerum has developed a novel treatment solution for patients with symptomatic BPH designed...
January 11, 2022

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens, Northwell Health’s Lenox Hill Hospital in New York City, and Ascension St. Vincent’s Riverside, Jacksonville, FL, are the first U.S. […]

Philips acquires Gilde portfolio company Vesper Medical to further expand its image-guided therapy devices portfolio

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire Vesper Medical Inc., a US-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical, a portfolio company of Gilde Healthcare, will further expand Philips’ portfolio of diagnostic and therapeutic devices with an […]

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today...

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase 3, developed for the treatment of calcific...

Gilde Healthcare portfolio company Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

Utrecht, The Netherlands & Basel, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Catherine Moukheibir and Ilise Lombardo as independent members of the company’s Board of Directors. Ms. Moukheibir has extensive...

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with...

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert and former Chief Executive Officer of Sage Therapeutics, with more than 25...

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted,...
Loading...
These were all messages
7fa93ceea8